Graduate:
`
`1981-
`1985
`
`Doctor of
`Medicine
`
`Intern:
`
`Residency:
`
`Fellowship:
`
`1985-
`1986
`
`Categorical
`Medicine
`
`Internal Medicine
`
`1986–
`1988
`
`University of South
`Alabama College of
`Medicine
`
`Brooke Army
`Medical Center
`
`Brooke Army
`Medical Center
`
`1988-
`1991
`
`Hematology/
`Medical Oncology
`
`Brooke Army
`Medical Center
`
`Licensure/Certifications
`Board Certification 1986
`
`
`
`West Point,
`New York
`
`Mobile,
`Alabama
`
`Fort Sam
`Houston, Texas
`
`Fort Sam
`Houston, Texas
`
`Fort Sam
`Houston, Texas
`
`Howard A. Burris, III, MD
`Curriculum Vitae
`1100 Charlotte Ave., Ste. 800, Nashville, Tennessee 37203 Ph: (615) 329-7274 Fax: (615) 340-1576 Email: howard.burris@sarahcannon.com
`
`
`
`
`Education
`Undergraduate:
`
`B.S. of Science
`
`1977-
`1981
`
`United States
`Military Academy
`
`
`Pennsylvania State Licensure
`
`
`
`
`
`Texas State Licensure
`
`Diplomate of the National
`Board of Medical Examiners
`
`Medical Doctor
`
`
`Diplomate of the American
`Board of Internal Medicine
`
`Medical Doctor
`
`
`Recertification Completed in
`2001 and 2011
`
`Tennessee State Licensure
`
`
`
`Diplomate of the American
`Board of Medical Oncology
`
`Medical Doctor
`
`
`
`Division of Health
`Related Boards
`
`Board Certification
`
`
`Division of Health
`Related Boards
`
`Board Certification
`
`
`Division of Health
`Related Boards
`
`
`1987
`
`
`1988
`
`
`1991
`
`
`1991
`
`
`1997
`
`
`
`
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 1 of 89
`
`

`

`
`
`
`
`
`
`Professional Employment
`President, Clinical
`2012 -
`Operations
`Present
`
`
`Executive Director,
`2011-
`Drug Development
`Present
`
`
`Chief Medical
`2006-
`Officer
`Present
`
`Director of Drug
`Development
`
`1997-
`2011
`
`Sarah Cannon
`
`
`Sarah Cannon Research Institute
`
`
`Sarah Cannon Research Institute
`
`Sarah Cannon Research Institute
`
`Associate
`
`1997-
`Present
`
`Tennessee Oncology, PLLC
`
`Director of Drug
`Development
`
`1990-
`1997
`
`Brooke Army Medical Center (Oncology
`Service)
`
`Associate Professor 1996-
`1997
`
`Director of Clinical
`Research
`
`1993-
`1995
`
`Associate Director
`of Clinical Research
`
`1992-
`1993
`
`Assistant Professor
`
`Staff (Hematology/
`Oncology Service)
`
`Staff (Hematology/
`Oncology Service)
`
`Clinical Instructor
`
`1991-
`1996
`
`1991-
`1997
`
`1991-
`1997
`
`1990-
`1991
`
`The University of Texas Health Science
`Center (Department of
`Medicine/Oncology)
`
`Cancer Therapy and Research Center of
`South Texas (Institute for Drug
`Development)
`
`Cancer Therapy and Research Center of
`South Texas (Institute for Drug
`Development)
`
`The University of Texas Health Science
`Center at San Antonio (Department of
`Medicine/Oncology)
`
`Brooke Army Medical Center
`(Department of Medicine)
`
`Cancer Therapy and Research Center of
`South Texas
`
`The University of Texas Health Science
`Center at San Antonio (Department of
`Medicine/Oncology)
`
`Nashville,
`Tennessee
`
`Nashville,
`Tennessee
`
`Nashville,
`Tennessee
`
`Nashville,
`Tennessee
`
`Nashville,
`Tennessee
`
`Fort Sam
`Houston, Texas
`
`San Antonio,
`Texas
`
`
`San Antonio,
`Texas
`
`
`San Antonio,
`Texas
`
`
`San Antonio,
`Texas
`
`
`Fort Sam
`Houston, Texas
`
`San Antonio,
`Texas
`
`San Antonio,
`Texas
`
`
`
`
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 2 of 89
`
`

`

`
`
`
`
`
`
`Professional Associations
`American Society of Clinical Oncology
`
`American College of Physicians
`
`American Society of Hematology
`
`Member (1991)
`Fellow (2010)
`Member (1989)
`Fellow (1995)
`Member (1993)
`
`Professional Honors
`Phi Kappa Phi
`Distinguished Military Graduate
`Letter of Commendation
`John Carpenter Outstanding Research
`Award
`
`Commander’s Award for Outstanding
`Research
`
`Promotion to Major
`Meritorious Service Medal
`The Surgeon General’s Physician
`Recognition Award
`
`Meritorious Service Medal (w/oak leaf
`cluster)
`
`Army Commendation Medal
`
`1991
`
`1991
`1992
`1994
`
`1994
`
`
`1997
`
`1980
`1981
`1986
`Academic Year 1987-
`1988
`
`US Military Academy
`US Military Academy
`Brooke Army Medical Center
`
`
`
`
`US Army
`Brooke Army Medical Center
`
`
`
`Brooke Army Medical Center
`
`
`Operation Joint Endeavor
`(Bosnia)
`
`US Army
`Southern Association for
`Oncology
`Massuchests General Hospital
`OncLive
`
`Promotion to Lieutenant Colonel
`President
`
`1997
`2001-2002
`
`Clinical Research Award
`Giant of Cancer Care Award
`
`2011
`2014
`
`Professional Memberships
`CTRC Clinical Practice Committee (Vice Chairman)
`Institute for Drug Development Project Committee
`Drug Development Program Committee (San Antonio
`Cancer Institute)
`Clinical Investigations Committee (San Antonio Cancer
`Institute)
`Hospice San Antonio, Inc., Board Member
`Brooke Army Medical Center Institutional Review Board
`
`1991-1995
`1991-1996
`1992-1996
`
`1992-1996
`
`1993-1996
`1995-1997
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 3 of 89
`
`

`

`
`
`
`
`
`
`Brooke Army Medical Center Clinical Investigations
`Committee
`Southern Association for Oncology, Board Member
`Minnie Pearl Research Foundation Board Member
`Gilda’s Club, Board Member
`Jack & Jill Foundation, Board Member
`
`ASCO Service
`ASCO Program Training Committee
`ASCO Clinical Practice Committee
`ASCO Education Committee
`ASCO Sponsorship Sub-Committee
`ASCO Scientific Program Committee
`ASCO Ethics Committee, Co-Chair
`ASCO Board of Directors
`ASCO Nominating Committee;
`Chair (2012-2013)
`ASCO Cancer Research Committee
`ASCO Research Community Forum Council;
`Chair (2014- 2015)
`ASCO Education Committee
`ASCO Conquer Cancer Foundation Board of Directors
`ASCO Conquer Cancer Foundation Development and
`Fundraising Committee
`
`Publications
`
`Manuscripts:
`
`1995-1997
`
`1997- 2005
`1998 - 2012
`1998-Present
`2014 - Present
`
`1999-2002
`2001-2004
`2002-2004
`2003-2005
`2004
`2004
`2006-2009
`2010-2013
`
`2011 – 2014
`2013 – Present
`
`2013 - 2016
`2016 – Present
`2016 - Present
`
`1. Wall, J., Burris, H., Von Hoff, D.D., Rodriguez, G., Kneuper-Hall, R., Shaffer, D., O'Rourke, T., Brown, T.,
`Weiss, G., Clark, G., McVea, S., Brown, J., Johnson, R., Friedman, C., Smith, B., Mann, W., Kuhn, J.: A
`phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864)
`given as an intravenous bolus every twenty-one days. Anticancer Drugs 3:337-345, 1992.
`
`2. Burris, H.A., Rothenberg, M., Kuhn, J.G., Von Hoff, D.D.: Clinical trials with the topoisomerase I inhibitors.
`Seminars in Oncology 19:663-669,1992.
`
`3. Burris, H.A., III, Hanauske, A.R., Johnson, R., Marshall, M.H., Kuhn, J.G., Hilsenbeck, S.G., Von Hoff, D.D.:
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 4 of 89
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony forming units in
`vitro. J Nat’l Cancer Inst 84:1816-1820, 1992.
`
`4. Von Hoff, D.D., McGill, J., Davidson, K., Forseth, B., Ebrahim, A., Burris, H.: Preclinical leads for innovative
`uses for etoposide. Seminars in Oncology 19(6) (suppl) 13:10-13, 1992.
`
`
`5. Shaffer, D.W., Burris, H.A., O'Rourke, T.J.: Testicular relapse in adult acute myelogenous leukemia. Cancer
`70:1541-1544, 1992.
`
`6. Rinaldi, D.A., Lippman, S.M., Burris, H.A., III, Chou, C., Von Hoff, D.D., Hong, W. K.: Phase II study of 13-
`cis-retinoic acid and alpha-2a interferon in patients with advanced squamous cell lung cancer. Anti-
`Cancer Drugs 4:33-36, 1993.
`
`7. Eckardt, J.R., Burris, H.A., Rothenberg, M., Von Hoff, D.D., Kuhn, J.: Topoisomerase-I inhibitors:
`Promising novel compounds. Contemp Oncol 3:47-60, 1993.
`
`8. Burris, H., Irvin, R., Kuhn, J., Kalter, S., Smith, L., Shaffer, D., Fields, S., Weiss, G., Eckardt, J., Rodriguez, G.,
`Vreeland, F., Bayssas, M., LeBail, N., Von Hoff, D.: A phase I clinical trial of taxotere given as either a 2-
`hour or as a 6-hour intravenous infusion. J Clin Oncol 11(5):950-958, 1993.
`
`9. Shaffer, D.W., Smith, L. S., Burris, H.A., Clark, G.M., Eckardt, J.R., Fields, S.M., Weiss, G.R., Rinaldi, D.A.,
`Bowen, K.J., Kuhn, J.G., Von Hoff, D.D.: A randomized phase I trial of chronic oral etoposide with or
`without granulocyte-macrophage colony stimulating factor in patients with advanced malignancies.
`Cancer Res 53:5929-5933, 1993.
`
`10. Rothenberg, M.L., Kuhn, J.G., Burris, H.A., III, Nelson, J., Eckardt, J.R., Tristan-Morales, M., Hilsenbeck,
`S.G., Weiss, G.R., Smith, L.S., Rodriguez, G.I., Rock, M.K., Terada, K., Von Hoff, D.D.: A phase I and
`pharmacokinetic trial of weekly CPT-11. J Clin Oncol 11(11):2194-2204, 1993.
`
`11. Vukelja, S.J., Baker, W.J., Burris, H.A., III, Keeling, J.H., Von Hoff, D.D.: Pyridoxine hydrochloride therapy
`for palmar-plantar erythrodysesthesia associated with taxotere. (Letter) J Nat’l Cancer Inst 85(17):1432-
`1433, 1993.
`
`12. Burris, H.A., III: The future of cytokines. Oncology (12) (suppl) 7:55-58, 1993.
`
`13. Burris, H.A., III: Preclinical pharmacology and phase I clinical trials of paclitaxel. Proceedings from
`Pharmaceutical Issues of Taxol, University of Arizona, pp. 8-13, 1993.
`
`14. Eckardt, J.R., Burris, H.A., III, Kuhn, J.G., Bissery, M.C., Klink-Alakl, M., Clark, G.M., Von Hoff, D.D.: Activity
`of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-
`forming units in vitro. J Nat’l Cancer Inst, 86 (1): 30-33, 1994.
`
`15. Burris HA 3rd: Pharmaceutical issues of paclitaxel. Preclinical pharmacology and phase I clinical trials.
`Ann Pharmacother 28(5 Suppl): S7 – 10. Review, 1994.
`
`16. Bowen, K., Fields, S., Burris, H.: Topoisomerase I inhibitors: a new class of anticancer agents. Adv in
`Oncology (10) 2:16-21, 1994.
`
`17. Muggia F.M., Burris H.A. III: Clinical development of topoisomerase-interactive drugs. Adv in
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 5 of 89
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Pharmacology 29B:1-31, 1994.
`
`
`18. Brown, T.D., O'Rourke, T.J., Kuhn, J.G., Craig, J.B., Havlin, K., Burris, H.A. III, Cagnola, J., Hamilton, J.M.,
`Grindey, G.B., Satterlee, W.G., Von Hoff, D.D.: Phase I trial of sulofenur (LY186641) given orally on a daily
`x 21 schedule. Anti-Cancer Drugs (5):151-159, 1994.
`
`19. Shimada, Y., Rothenberg, M., Hilsenbeck, S.G., Burris, H.A., III, Degen, D., Von Hoff, D.D.: Activity of CPT-
`11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
`Anti-Cancer Drugs (5): 202-206, 1994.
`
`20. O'Rourke, T.J., Brown, T.D., Havlin, K., Kuhn, J.G., Craig, J.B., Burris, H.A., Satterlee, W.G., Tarassoff, P.G.,
`Von Hoff, D.D.: Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.
`(Letter) Eur J Cancer 30A(3):417-418, 1994.
`
`21. Zimmerman, G.C., Keeling, J.H., Lowry, M., Burris, H.A., Von Hoff, D.D.: Prevention of docetaxel-induced
`erythrodypesthesia with local hypothermia. (Letter) J Nat’l Cancer Inst 86(7):557-558, 1994.
`
`22. Eckardt, J.R., Campbell, E., Burris, H.A., Weiss, G.R., Rodriguez, G.I., Fields, S.M., Thurman, A.M., Peacock,
`N.W., Cobb, P., Rothenberg, M.L., Ross, M.E., Von Hoff, D.D.: A phase II trial of DaunoXome7, liposome
`encapsulated daunorubicin in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol
`17(6):498-501, 1994.
`
`23. Von Hoff, D.D., Burris, H.A., III, Eckardt, J., Fields, S.M., Chen, S.-F., Kuhn, J.G.: Preclinical and phase I trials
`of topoisomerase I inhibitors. Cancer Chemother and Pharmacol 34(Suppl):41-45, 1994.
`
`24. Burris, H.A. III, Eckardt, J.R., Awada, A., Fields, S., Rodriguez, G.I., Smith, S., Weiss, G.R., Rinaldi, D.A., Clark
`G., Casenave, L., Von Hoff, D.D., Kuhn, J.G.: Phase I and pharmacokinetic studies of topotecan
`administered as a 72- or 120-Hour continuous infusion. Anti-Cancer Drugs (5):394-402, 1994.
`
`25. Zimmerman, G.C., Keeling, J.H., Burris, H.A., Cook, G., Irwin, R., Kuhn, J., McCollough, M.L., Von Hoff, D.D.:
`Acute cutaneous reactions to taxotere (RP 56976), a new chemotherapeutic agent. Ann Int Med (In
`Press), 1994.
`
`26. Cobb, P.W., Clark, G.M., Kuhn, J.G., Kirshenbaum, M.R., Burris, H.A. III, Von Hoff, D.D.Activity of DMP840,
`a new bis-naphthalimide, on primary human tumor colony-forming units. J Nat’l Cancer Inst 86:1462-
`1465, 1994.
`
`27. Burris, H.A., III and Fields, S.: Summary of data from in vitro and phase I navelbine studies. Seminars in
`Oncology 21:14-20, 1994.
`
`28. Fields, S.M., Burris, H.A., III: Irinotecan: a new topoisomerase I inhibitor with promising antitumor
`activity. Highlights in Antineoplastic Agents 12:68-72, 1994.
`
`29. O'Rourke, T.J., Weiss, G.R., New, P., Burris, H.A., Rodriguez, G., Eckardt, J., Hardy, J., Kuhn, J.G., Fields,
`S.M., Clark, G.M., Von Hoff, D.D.: Phase I clinical trial of ormaplatin (Tetraplatin, NSC363812) given on a
`daily times five every 28 day schedule. Anti-Cancer Drugs 5(5):520-526, 1994.
`
`
`30. Weiss, G.R., Kuhn, J.R., Rizzo, J., Smith, L.S., Rodriguez, G.I., Eckardt, J.R., Burris, H.A. III, Fields, S.,
`VanDenBerg, C., Von Hoff, D.D.: A phase I and pharmacokinetic study of 2-chlorodeoxyadenosine in
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 6 of 89
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`patients with solid tumors. Cancer Chemother Pharmacol 35:397-402, 1995.
`
`31. Bedikian, A.Y., Weiss, G.R., Legha, S.S., Burris, H.A., Eckardt, J.R., Jenkins, J., Eton, O., Buzaid, A.C.,
`Smetzer, L., Von Hoff, D.D., Benjamin, R.S.: Phase II trial of docetaxel (taxotere, RP56976) in patients with
`advanced cutaneous malignant melanoma previously untreated with chemotherapy. J Clin Oncol
`13(12):2895-2899, 1995.
`
`32. Rinaldi, D.A., Burris, H.A., Dorr, F.A., Woodworth, J.R., Kuhn, J.G., Eckardt, J.R., Rodriguez, G., Corso, S.W.,
`Fields,S.M., Nelson, J., Clark, G., Farie,s D., Lu, P., Von Hoff, D.D.: Initial phase I evaluation of the novel
`thymidylate synthase inhibitor, LY231514, utilizing the modified continual reassessment method for dose
`escalation. J Clin Oncol 13(11):2842-2850, 1995.
`
`33. Ravdin P.M., Burris H.A., Cook G., et al: Phase II trial of docetaxel in advanced anthracycline-
`resistant or anthracenedione-resistant breast cancer. J Clin Oncol 13:2879-2885, 1995.
`
`34. Grunberg, S.M., Burris H., III, Livingston, R.: The price of success. (Letter to the Editor) J Clin Oncol 13:797-
`798, 1995
`
`35. Burris, H.S., Fields S., Peacock, N.: Docetaxel (Taxotere) in combination: a step forward. Semin Oncol
`22(6 Suppl 13):35-40, 1995.
`
`36. Kolesar, J.M., Kuhn, J.G., Burris, H.A.: Detection of a point mutation in NQ01 (DT-diaphorase) in a patient
`with colon cancer. J Nat’l Cancer Inst 87(13:1022-4, 1995.
`
`37. Battafarano D. F., Zimmerman, G.C., Older, S.A., Keeling, J.H., Burris, H.A.: Docetaxel (Taxotere)
`associated scleroderma-like changes of the lower extremities. A report of three cases. Cancer 78(1):110-
`5, 1995.
`
`38. Zimmerman, G.C., Keeling, J.H., Burris, H.A., Cook, G., Irvin, R., Kuhn, J., McCollough, M.L., Von Hoff, D.D.:
`Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol 131(2):202-6,
`1995.
`
`39. Ritch PS, Keever C, Schiller J, Rivkin S, Witt PL, Grossberg SE, Truitt RL, Burris H, von Hoff DD, Vaickus L:
`Phase IA/IB evaluation of mammalian cell-derived glycosylated recombinant human interleukin (SIGOSIX)
`before and after cytotoxic chemotherapy. Ann N Y Acad Sci 21: 762: 359 – 360, 1995.
`
`40. Rothenberg, M.L., Eckardt, J.R., Kuhn, J.G., Burris, H.A., III, Nelson, J., Hilsenbeck, S.G., Rodriguez, G.I.,
`Thurman, A.M., Smith, L.S., Eckhardt, S.G., Weiss, G.R., Elfring, G.L., Rinaldi, D.A., Schaaf, L.J., Von Hoff,
`D.D.: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin
`Oncol 14(4):1128-1135, 1996.
`
`41. Jones S.F, Burris H.A. III: Vinorelbine: A new antineoplastic drug for the treatment of non-small cell lung
`cancer. Annals of Pharmacotherapy 30(5):501-506, 1996.
`
`42. Rothenberg, M.L., Moore, M.J., Cripps, M.C., Andersen, J.S., Portenoy, R.K., Burris, H.A., III, Green, M.R.,
`Tarassoff, P.G., Brown, T.D., Casper, E.S., Storniolo, A.-M., Von Hoff, D.D.: A phase II trial of gemcitabine
`in patients with 5-FU-refractory pancreas cancer. Annals of Oncol 7:347-353, 1996.
`
`43. Eckhardt, S.G., Burris, H.A., Eckardt, J.R., Weiss, G., Rodriquez, G., Rothenberg, M., Rinaldi, D., Barrington,
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 7 of 89
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`R., Kuhn, J.G., Masuo, K., Sudo, K., Atsumi, R., Oguma, T., Higashi, L., Fields, S., Smetzer, Von Hoff, D.D.: A
`phase I clinical and pharmacokinetic study of the angiogenesis inhibitor, tecogalan sodium. Annals of
`Oncol 7:491-496, 1996.
`
`44. Burris H.A. III: Optimal use of docetaxel (Taxotere): Maximizing it’s potential. Anti-Cancer Drugs
`7(Suppl)2:25-28, 1996.
`
`45. Burris H.A. III: Objective outcome measures of quality of life. Oncology 10(11 Suppl):131-135, 1996.
`
`46. Burris, H., Hesketh, P., Cohn, J., Moriconi, W., Ryan, T., Friedman, C., Fitts, D.: Efficacy and Safety of Oral
`Granisetron versus Oral Oprochlorperazine in Preventing Nausea and Emesis in Patients Receiving
`Moderately Emetogenic Chemotherapy. Cancer J Sci Am 2(2):85, 1996.
`
`47. Cunningham, D., Zalcberg, J., Smith, I., Gore, M., Pazdur, R., Burris, H., Meropol, N.J., Kennealey, G.,
`Seymour, L.: ‘Tomudex’ (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour
`activity in a range of solid tumors. ‘Tomudex’ International Study Group. Ann Oncol 7(2):179-82, 1996.
`
`48. Jones, S.F., Burris, H.A.: Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Prac 4(1):51-3,
`1996.
`
`49. New, P.Z., Jackson, C.E., Rinaldi, D., Burris, H., Barohn, R.J.: Peripheral neuropathy secondary to
`docetaxel. Neurology 46(1):108-11, 1996.
`
`50. Burris H.A. III, Storniolo A.M.: Assessing clinical benefit in the treatment of pancreas cancer: Gemcitabine
`compared to 5-Fluorouracil. European Journal of Cancer 33(Suppl)1:S18-22, 1997.
`
`51. Burris H.A. III, Dieras V.C., Tunca M., Earhart R.H., Eckardt J.R., Rodriguez G.I., Shaffer D.S., Fields
`S.M., Campbell E., Schaaf L., Kasunic D., Von Hoff D.D.: Phase I study with the DNA sequence-specific
`agent adozelesin. Anti-Cancer Drugs 8(6):588-596, 1997.
`
`52. Burris, H.A., III, Moore, M.J., Andersen, J., Green, M.R., Rothenberg, M.L., Modiano, M.R., Cripps,
`M.C., Portenoy, R.K., Storniolo, A.M., Tarrassoff, P., Nelson, R., Von Hoff, D.D.: Improvements in
`survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas
`cancer: A randomized trial. J Clin Oncol 15:2403-2413, 1997.
`
`53. Creemers, G.J., Gerrits, C.J.H., Eckardt, J.R., Schellens, J.H.M., Burris, H.A., Planting, A.S.Th.,
`Rodriguez, G.I., Loos, W.J., Hudson, I., Broom, C., Verweij, J., Von Hoff, D.D.: Phase I and
`pharmacologic study of oral topotecan administered twice daily for 21-days to adult patients with
`solid tumors. J Clin Oncol 15:1087-1093, 1997.
`
`54. Rowinsky E., Smith L., Rodriguez G., White L., Drengler R., Von Hoff D., Peacock N., Aylesworth C.,
`Burris H.A. III, Ravdin P., Bellet R.: Docetaxel in combination with fluorouracil: Study design and
`preliminary results. Oncology 11 (6 Suppl 6):35-35, 1997.
`
`
`55. Raymond E., Burris H.A., Rowinsky E.K., Eckardt J.R., Rodriguez G., Smith L., Weiss G., Von Hoff D.D.:
`Phase I study of daily times five topotecan and single injection of cisplatin in patients with previously
`untreated non-small cell lung carcinoma. Ann of Oncol 8(10):1003-1008, 1997.
`
`56. Benedetti, J.K., Burris, H.A., Balcerzak, S.P., MacDonald, J.S.: Phase II trial of topotecan in advanced
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 8 of 89
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`gastric cancer: a Southwest Oncology Group study. Invest New Drugs 15(3):261-4, 1997.
`
`57. Burris, H.A.: Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology
`11(Suppl 8):50-2, 1997
`
`58. Bruno R., Hille D., Riva A., Vivier N., ten Bokkel Huinnink W.W., van Oosterom A.T., Kaye S.B., Verweij
`J., Fossela F.V., Valero V., Rigas J.R., Seidman A.D., Chevallier B., Fumoleau P., Burris H.A., Ravdin P.M.,
`Sheiner L.B.: Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in
`patients with cancer. J Clin Oncol 16(No. 1):187-196, 1998.
`
`59. Burris H.A. III: Topotecan: Incorporating it into the treatment of solid tumors. The Oncologist 3:1-3,
`1998.
`
`60. Rothenberg M.L., Sharma A., Weiss G.R., Villalona-Calero M.A., Eckardt J.R., Aylesworth C., Kraynak
`M., Rinaldi D.A., Rodriguez G.I., Burris, H.A., Eckhardt S.G., Stephens C.D., Forral K., Nichol S., Von Hoff
`D.D.: Phase I trial of paclitaxel and gemcitabine in patients with refractory solid tumors. Ann of Oncol
`9(7): 733-738, 1998.
`
`61. Schilsky R.L., Hohneker J., Ratain M.J., Janisch L., Smetzer L., Lucas V.S., Khor S.P., Diasio R., Von Hoff
`D.D., Burris H.A.: Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients
`with advanced cancer. J Clin Oncol 16(4):1450-1457, 1998.
`
`62. Hainsworth J.D., Burris H.A., Erland J.B., Thomas M., Greco F.A.: Phase I trial of docetaxel
`administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol 16(6):2164-
`2168, 1998.
`
`63. Burris, H.: Weekly schedules of docetaxel. Semin Oncol 25(6 Suppl 13):21-3, 1998.
`
`64. Gerrits, C.J., Burris, H., Schellens, J.H., Planting, A.S., van den Burg, M.E., Rodriguez, G.I., van Beurden,
`V., Loos, W.J., Hudson, I., Fields, S., Verweij, J., Von Hoff, D.D.: Five days of oral topotecan (Hycamtin),
`a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 34(7):1030-5,
`1998.
`
`65. Valero, V., Jones, S.E., Von Hoff, D.D., Booser, D.J., Mennel, R.G., Ravdin, P.M., Holmes, F.A., Rahman,
`Z., Schottstaedt, M.W., Erban, J.K., Esparza-Guerra, L., Earhart, R.H., Hortobagyi, G.N., Burris, H.A.: A
`phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol
`16(10):3362-8, 1998.
`
`66. Peacock, N.W., Burris, H.A., Dieras, V., Smith, L., Rodriguez, G.I., Eckardt, J.R., Jones, S.F., Hardy, J.,
`Hohneker, J., Bigley, J., Von Hoff, D.D.: A phase I trial of vinorelbine in combination with mitoxantrone
`in patients with refractory solid tumors. Invest New Drugs 16(1):7-43, 1998.
`
`
`67. Burris, H.A., Raymond, E., Awada, A., Kuhn, J.G., O’Rourke, T.J., Brentzel, J., Lynch, W., King, S.Y.,
`Brown, T.D., Von Hoff, D.D.: Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC
`368390) in combination with cisplatin in patients with advanced malignancies. Invest New Drugs
`16(1):19-27, 1998.
`
`68. Hammond, L.A., Eckardt, J.R., Ganapathi, R., Burris, H.A., Rodriguez, G.A., Eckhardt, S.G., Rothenberg,
`M.L., Weiss, G.R., Kuhn, J.G., Hodges, S., Von Hoff, D.D., Rowinski, E.K.: A phase I and translational
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 9 of 89
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
`Clin Cancer Res 4(6):1459-67, 1998.
`
`69. Gerrits, C.J., Burris, H., Schellens, J.H., Eckardt, J.R., Planting, A.S., van der Burg, M.E., Rodriguez, G.I.,
`Loos, W.J., van Beurden, V., Hudson, I., Fields, S., Von Hoff, D.D., Verweij, J: Oral topotecan given
`once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
`Clin Cancer Res 4(5):1153-8, 1998.
`
`70. Villalona-Calero, M.A., Eckardt, J., Burris, H., Kraynak, M., Fields-Jones, S., Bazan, C., Lancaster, J.,
`Hander, T., Goldblum, R., Hammond, L., Bari, A., Drengler, R., Rothenberg, M., Hadovsky, G., Von Hoff,
`D.D.: A phase I trial of human corticotropin-releasing factor (hCRF) in patients with peritumoral brain
`edema. Ann Oncol 9(1):71-7, 1998.
`
`71. Eckhardt, S.G., Baker, S.D., Eckardt, J.R., Burke, T.G., Warner, D.L., Kuhn, J.G., Rodriguez, G., Fields, S.,
`Thurman, A., Smith, L., Rothenberg, M.L., White, L., Wissel, P., Kunka, R., DePee, S., Littlefield, D.,
`Burris, H.A., Von Hoff, D.D., Rowinsky, E.K.: Phase I and pharmacokinetic study of GI147211, a water-
`soluble camptothecin analogue, administered for five consecutive days every three weeks. Clin
`Cancer Res 4(3):595-604, 1998.
`
`72. Burris, H.A., Voge., C.L., Castro, D., Mishra, L., Schwarz, M., Spencer, S., Oakes, D.D., Korey, A.,
`Orenberg, E.K.: Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for
`accessible solid tumors: a multicenter pilot study. Otolaryngol Head Neck Surg 118(4):496-503, 1998.
`
`73. Burris, H.A.: The evolving role of oral topotecan. Semin Hematol 36(4 Suppl 8):26-32, 1999.
`
`74. Villalona-Calero, M.A., Weiss, G.R., Burris, H.A., Kraynak, M., Rodriguez, G., Drengler, R.L., Eckhardt,
`S.G., Reigner, B., Moczygemba, J., Burger, H.U., Griffin, T., Von Hoff, D.D., Rowinsky, E.K.: Phase I and
`pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in
`patients with advanced solid malignancies. J Clin Oncol 17(6):1915, 1999.
`
`75. Rinaldi, D.A., Kuhn, J.G., Burris, H.A., Dorr, F.A., Rodriguez, G., Eckhardt, S.G., Jones, S., Woodworth,
`J.R., Baker, S., Langley, C., Mascorro, D., Abrahams, T., Von Hoff, D.D: A phase I evaluation of multi-
`targeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual
`reassessment method for dose escalation. Cancer Chemother Pharmacol 44(5):372-80, 1999.
`
`76. Hesketh, P.J., Crowley, J.J., Burris, H.A., Williamson, S.K., Balcerzak, S.P., Peereboom, D., Goodwin,
`J.W., Gross, H.M., Moore, D.F. Jr., Livingston, R.B., Gandara, D.R.: Evaluation of docetaxel in
`previously untreated extensive-stage small cell lung cancer: a Southwest Oncology Group phase II
`trial. Cancer J Sci Am 5(4):237-41, 1999.
`
`
`77. Hainsworth, J.D., Burris, H.A., Greco, F.A.: Weekly administration of docetaxel (Taxotere): summary
`of clinical data. Semin Oncol 26(3 Suppl 10):19-24, 1999.
`
`78. Burris, H.A.: Single-agent docetaxel (Taxotere) in randomized phase III trials. Semin Oncol 26(3 Suppl
`9):1-6, 1999.
`
`79. Hainsworth, J.D., Burris, H.A., Erland, J.B., Morrissey, L.H., Meluch, A.A., Kalman, L.A., Hon, J.K., Scullin,
`D.D. Jr., Smith, S.W., Greco, F.A.: Phase I/II trial of paclitaxel by 1-hour infusion carboplatin, and
`gemcitabine in the treatment of patients with advanced non-small cell lung carcinoma. Cancer
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 10 of 89
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`85(6):1269-76, 1999.
`
`80. Petit, T., Aylesworth, C., Burris, H., Ravdin, P., Rodriguez, G., Smith, L., Peacock, N., Smetzer, L., Bellet,
`R., Von Hoff, D.D., Rowinsky, E.K.: A phase I study of docetaxel and 5-fluorouracil in patients with
`advanced solid malignancies. Ann Oncol 10(2):223-9, 1999.
`
`81. Hainsworth, J.D., Burris, H.A., Morrissey, L.H., Greco, F.A.: Phase I trial of paclitaxel, carboplatin, and
`topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of
`patients with advanced, refractory cancer. Cancer 1;85(5):1179-85, 1999.
`
`82. Diab, S.G., Baker, S.D., Joshi, A., Burris, H.A., Cobb, P.W., Villalona-Calero, M.A., Eckhardt, S.G., Weiss,
`G.R., Rodriguez, G.I., Drengler, R., Kraynak, M., Hammond, L., Finizio, M., Von Hoff, D.D., Rowinsky,
`E.K.: A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced
`solid tumors. Clin Cancer Res 5(2):299-308, 1999.
`
`83. Pazdur, R., Royce, M.E., Rodriguez, G.I., Rinaldi, D.A., Patt, Y.Z., Hoff, P.M., Burris, H.A.: Phase II trial of
`docetaxel for cholangiocarcinoma. Am J Clin Oncol 22(1):78-81, 1999.
`
`84. Gerrits, C.J., Schellens, J.H., Burris, H., Eckardt, J.R., Planting, A.S., van der Burg, M.E., Rodriguez, G.I.,
`Loos, W.J., van Beurden, V., Hudson, I., Von Hoff, D.D., Verweij, J.: A comparison of clinical
`pharmacodynamics of different administration schedules or oral topotecan. Clin Cancer Res 5(1):69-
`75, 1999.
`
`85. Fields-Jones S, Koletsky A, Wilding G, O’Rourke M, O’Rourke T, Eckardt J, Yates B, McGuirt C, Burris HA
`3rd: Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory
`prostate cancer: a phase II trial. Ann Oncol 10(11): 1307 – 1310, 1999.
`
`86. Burris HA: Docetaxel (Taxotere) in HER-2 positive patients and in combination with trastuzumab
`(Herceptin). Semin Oncol 27(2 Suppl 3): 19-23. Review, 2000.
`
`87. Hainsworth JD, Burris HA, Litchy S, Erland JB, Hon JK, Briere JE, Greco FA: Gemcitabine and
`vinorelbine in the second-line treatment of non-small cell lung cancer: A Minnie Pearl Cancer
`Research Network phase II trial. Cancer 88:1353-1358, 2000.
`
`88. Hainsworth JD, Burris HA, Morrissey LH, Thomas M, Erland JB, Butts JA, Joseph G, Kalman L, Greco FA:
`Paclitaxel, carboplatin and vinorelbine in the treatment of advanced non-small cell lung cancer: A
`phase II trial of the Minnie Pearl Cancer Research Network. Cancer Journal Sci Am 6:151-156, 2000.
`
`89. Hainsworth JD, Burris HA, Morrissey LH, Litchy S, Scullin DC JR, Bearden JD, Richards P, Greco FA:
`Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin’s
`lymphoma. Blood 95:3052-3056, 2000.
`
`90. Hainsworth JD, Burris HA, Litchy S, Morrissey LH, Barton JH, Bradof JE, Greco FA: Weekly docetaxel in
`the treatment of elderly patients with advanced non-small cell lung cancer: A Minnie Pearl Cancer
`Research Network phase II trial. Cancer 89:328-333, 2000.
`
`91. Greco FA, Burris HA, Erland JB, Cray JR, Kalman LA, Schreeder MT, Hainsworth JD: Carcinoma of
`unknown primary site; Long-term follow-up after treatment with paclitaxel, carboplatin, and
`etoposide. Cancer 89:2655-2660, 2000.
`
`NOVARTIS EXHIBIT 2002
`Breckenridge v. Novartis, IPR 2017-01592
`Page 11 of 89
`
`

`

`
`
`
`
`92. Greco FA, Erland JB, Morrissey LH, Burris HA, Hermann RC, Steis R, Thompson D, Gray J, Hainsworth
`JD: Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin.
`Ann Oncol 11:211-215, 2000.
`
`93. Hainsworth JD, Burris HA, Greco FA: Weekly docetaxel in the treatment of elderly or poor
`performance status patients with advanced non-small cell lung cancer. Cancer Conf Highlights 4:2-4,
`2000.
`
`94. Meluch AA, Burris HA, Greco FA, Hainsworth JD: Gemcitabine and paclitaxel combination therapy in
`transitional cell carcinoma of the urothelium. Eur J Cancer 36:S30-S33, 2000.
`
`95. Greco FA, Burris HA, Hainsworth JD: Gemcitabine, paclitaxel, and carboplatin for advanced non-small
`cell lung cancer. Oncology 14(suppl 4):31-34, 2000.
`
`96. Burris HA 3rd, Hainsworth JD, Erland JB, Morrissey LH, Kalman LA, Hon JK, Scullin DC Jr, Smith SW,
`Greco FA: Phase II trial evaluating triplet chemotherapy using gemcitabine, paclitaxel, and carboplatin
`in the treatment of patients with advanced non-small cell lung cancer. Semin Oncol 27 (1 suppl 2):9-
`13, 2000.
`
`97. Schilsky RL, Bukowski R, Burris HA 3rd, Hochster H, O’Rourke M, Wall JG, Mani S, Bonny T, Levin J,
`Hohneker J: A multicenter phase II study of a five-day regimen of oral 5-fluoruoracil plus eniluracil
`with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol 11(4): 415 – 420,
`2000.
`
`98. Burris HA 3rd: Docetaxel (Taxotere) in the treatment of cancer. Semin Oncol 27 (2 Suppl 3): 1 – 2.
`Review, 2000.
`
`99. Friedman CJ, Burris HA 3rd, Yocom K, Blackburn LM, Gruben D: Oral granisetron for the prevention of
`acute late onset nausea and vomiting in patients treated with moderately emetogenci chemotherapy.
`Oncologist 5(2): 136 – 143, 2000.
`
`100. Hainsworth JD, Burris HA, Calvert SW, Willcutt NT, Scullin DC Jr, Bramham J, Greco FA: Gemcitabine in
`the second-line therapy of patients with carcinoma of unknown primary site: A phase II trial of the
`Minnie Pearl Cancer Research Network. Cancer Investigation 19:335-339, 2001.
`
`101. Hainsworth JD, Burris HA, Meluch AA, Baker MN, Morrissey LH, Greco FA: Paclitaxel, carboplatin and
`long-term continuous infusion 5-flourouracil in the treatment of advanced squamous carcinoma:
`results of a phase II trial. Cancer 92:642-649, 2001.
`
`102. Greco FA, Gray J, Burris HA, Erland JB, Morrissey LH, Hainsworth JD: Taxane-based chemotherapy for
`patients with carcinoma of unknown primary site. Cancer J Sci Am 7:203-211, 2001.
`
`103. Greco FA, Burris HA, Gray JR, Raefsky EL, Dobbs C, Smith S,